Historical record - last NADAC effective date: 7/17/2024

Product Information

METHOTREXATE 250 MG/10 ML VIAL is a generic product labeled by Accord Healthcare Inc., priced at $0.8029 per ML under NDC 16729027703. Its NADAC has been published 350 times since May 7, 2014.

FDA first approved this application on Apr 30, 2007. Its Orange Book therapeutic-equivalence code is AP.

METHOTREXATE 250 MG/10 ML VIAL

Methotrexate
$0.8029per ML

Strength

25 mg/mL

NDC

16729027703

Classification

Generic

Dosage Form

INJECTION

Route

INTRA-ARTERIAL; INTRAMUSCULAR; INTRATHECAL; INTRAVENOUS

Effective Date

7/17/2024

Active Ingredients

METHOTREXATE

Approval Type

Generic (ANDA)

FDA Application

ANDA040716

FDA Approved

4/30/2007

TE Code

AP

On Market Since

3/7/2014

Pharmacological Classes

Folate Analog Metabolic Inhibitor
Folic Acid Metabolism Inhibitors

Price Statistics

The NADAC for METHOTREXATE 250 MG/10 ML VIAL has been published 350 times since May 7, 2014, and over the history we have for it it has declined 6.0%. The table below summarizes its recorded NADAC range and movement.

Current price$0.8029 per ML
All-time high$1.1148 (Jul 15, 2015)
All-time low$0.6670 (Sep 21, 2016)
Median price$0.7998
Average price$0.7827
Largest weekly change+42.2% (Jun 22, 2016)
Weeks tracked350
Tracking sinceMay 7, 2014

Price History

1W

N/A

1M

N/A

3M

N/A

6M

N/A

1Y

N/A

3Y

+17.3%

5Y

+0.4%

All

-6.0%

Last surveyed Aug 14, 2024 — this NDC no longer appears in the current weekly NADAC file.

Generic Alternatives

The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 20% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of METHOTREXATE 250 MG/10 ML VIAL?

The current National Average Drug Acquisition Cost (NADAC) for METHOTREXATE 250 MG/10 ML VIAL, manufactured by Accord Healthcare Inc., is $0.8029 per ML (NDC 16729027703), effective Aug 14, 2024.

How has the price of METHOTREXATE 250 MG/10 ML VIAL changed over time?

Over the history we have for it, the NADAC for METHOTREXATE 250 MG/10 ML VIAL has declined 6.0%. It has been tracked across 350 weekly CMS publications since May 7, 2014.

What are the highest and lowest recorded NADAC prices for METHOTREXATE 250 MG/10 ML VIAL?

Since May 7, 2014, the NADAC for METHOTREXATE 250 MG/10 ML VIAL has ranged from a low of $0.6670 (Sep 21, 2016) to a high of $1.1148 (Jul 15, 2015), with a median of $0.7998 per ML.

Are there cheaper alternatives to METHOTREXATE 250 MG/10 ML VIAL?

Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, METHOTREXATE 1 GRAM/40 ML VIAL, is $0.6450 per ML — about 20% below METHOTREXATE 250 MG/10 ML VIAL.

Who manufactures METHOTREXATE 250 MG/10 ML VIAL?

METHOTREXATE 250 MG/10 ML VIAL (NDC 16729027703) is labeled by Accord Healthcare Inc., and CMS classifies it as a generic product.